Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity - PubMed (original) (raw)
. 2011 Feb 24;117(8):2469-75.
doi: 10.1182/blood-2010-09-307280. Epub 2010 Dec 21.
Lars Bullinger, Andrea Corbacioglu, Mathijs A Sanders, Claudia A J Erpelinck, Bas J Wouters, Sonja C van der Poel-van de Luytgaarde, Frederik Damm, Jürgen Krauter, Arnold Ganser, Richard F Schlenk, Bob Löwenberg, Ruud Delwel, Hartmut Döhner, Peter J M Valk, Konstanze Döhner
Affiliations
- PMID: 21177436
- DOI: 10.1182/blood-2010-09-307280
Free article
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen et al. Blood. 2011.
Free article
Abstract
We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPA(dm)) versus single mutations (CEBPA(sm)) in 1182 cytogenetically normal acute myeloid leukemia (AML) patients (16-60 years of age). We identified 151 (12.8%) patients with CEBPA mutations (91 CEBPA(dm) and 60 CEBPA(sm)). The incidence of germline mutations was 7% (5 of 71), including 3 C-terminal mutations. CEBPA(dm) patients had a lower frequency of concurrent mutations than CEBPA(sm) patients (P < .0001). Both, groups were associated with a favorable outcome compared with CEBPA(wt) (5-year overall survival [OS] 63% and 56% vs 39%; P < .0001 and P = .05, respectively). However, in multivariable analysis only CEBPA(dm) was a prognostic factor for favorable OS outcome (hazard ratio [HR] 0.36, P < .0001; event-free survival, HR 0.41, P < .0001; relapse-free survival, HR 0.55, P = .001). Outcome in CEBPA(sm) is dominated by concurrent NPM1 and/or FLT3 internal tandem duplication mutations. Unsupervised and supervised GEP analyses showed that CEBPA(dm) AML (n = 42), but not CEBPA(sm) AML (n = 18), expressed a unique gene signature. A 25-probe set prediction signature for CEBPA(dm) AML showed 100% sensitivity and specificity. Based on these findings, we propose that CEBPA(dm) should be clearly defined from CEBPA(sm) AML and considered as a separate entity in the classification of AML.
Similar articles
- Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Green CL, et al. J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439648 - Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Ann Hematol. 2016. PMID: 26537612 - Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Schlenk RF, et al. N Engl J Med. 2008 May 1;358(18):1909-18. doi: 10.1056/NEJMoa074306. N Engl J Med. 2008. PMID: 18450602 - Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Port M, et al. Ann Hematol. 2014 Aug;93(8):1279-86. doi: 10.1007/s00277-014-2072-6. Epub 2014 May 7. Ann Hematol. 2014. PMID: 24801015 Review. - Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
Mendoza H, Podoltsev NA, Siddon AJ. Mendoza H, et al. Int J Lab Hematol. 2021 Jul;43 Suppl 1:86-95. doi: 10.1111/ijlh.13517. Int J Lab Hematol. 2021. PMID: 34288448 Review.
Cited by
- Recent progress in AML with recurrent genetic abnormalities.
Ishikawa Y. Ishikawa Y. Int J Hematol. 2024 Oct 1. doi: 10.1007/s12185-024-03848-3. Online ahead of print. Int J Hematol. 2024. PMID: 39352624 - Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
Zhao Y, Huang Y, Jiang L, Zhang Y, Liu F, Yan P, Yu G, Liu J, Jiang X. Zhao Y, et al. Ann Hematol. 2024 Sep;103(9):3595-3604. doi: 10.1007/s00277-024-05884-9. Epub 2024 Jul 18. Ann Hematol. 2024. PMID: 39020042 - CEBPA Restrains the Malignant Progression of Breast Cancer by Prompting the Transcription of SOCS2.
Wang JL, Ji WW, Huang AL, Liu Z, Chen DF. Wang JL, et al. Mol Biotechnol. 2024 May 22. doi: 10.1007/s12033-024-01189-4. Online ahead of print. Mol Biotechnol. 2024. PMID: 38775935 - Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, Uy GL, Stock W, Byrd JC, Hiddemann W, Braess J, Spiekermann K, Metzeler KH, Herold T, Eisfeld AK. Archer KJ, et al. J Hematol Oncol. 2024 May 3;17(1):28. doi: 10.1186/s13045-024-01553-6. J Hematol Oncol. 2024. PMID: 38702786 Free PMC article. - CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.
Tien FM, Hou HA. Tien FM, et al. Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773-5. Online ahead of print. Int J Hematol. 2024. PMID: 38671183 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous